Background Dupilumab, the first biological drug to be approved for the treatment of
moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy …

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease. It has a
complex pathophysiology, with a combination of immune dysregulation and intrinsic barrier …

Dupilumab, an IL-4/IL-13 receptor blocker, has been linked to emergent seronegative
inflammatory arthritis and psoriasis that form part of the spondyloarthropathy spectrum. We …

Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal
bullous disease of the skin. First-line treatment of systemic corticosteroids may cause …

Asthma is a heterogeneous respiratory disease characterized by usually reversible
bronchial obstruction, which is clinically expressed by different phenotypes driven by …

Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and
adults, including a large number of adults of reproductive age. Several guidelines for the …

Atopic dermatitis (AD) is an inflammatory disorder centered around loss of epidermal barrier
function, and T helper 2 (Th2) immune responses. The current understanding of disease …

Atopic dermatitis (AD) is a clinically heterogenous, inflammatory skin condition with a high
impact on patients' daily activities that remains difficult to treat. The knowledge acquired over …

Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a high
prevalence worldwide, including countries from Asia, Africa, and Latin America, and in …

Background Atopic dermatitis (AD) is a common chronic, inflammatory skin condition. The
pathogenesis of AD involves many cytokines that utilize the Janus kinase/signal transducer …